Maravai LifeSciences Holdings, Inc. (MRVI)
Valuation Overview•Is Maravai LifeSciences Holdings, Inc. Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
Fragile underlying quality score of 39/100; weak margins or elevated debt leverage warrant caution.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Mixed fundamental profile with offsetting strengths and weaknesses.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
MRVI struggles with subpar profitability and pressured margins. This is backed by a fortress balance sheet, holding significant net cash ($181M) and minimal debt risk.
The company is facing top-line contraction (-40.5% 3Y CAGR) paired with stable bottom-line earnings. The company maintains healthy operational efficiency with a 21.9% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $65.8M | -28.3% | -40.5% | -8.1% | — | |
| EBITDA | $15.5M | — | -55.5% | — | — | |
| Net Income | -$3.7M | +9.7% | — | — | — | |
| EPS (Diluted) | $-0.03 | +13.3% | — | — | — | |
| Free Cash Flow | $4.2M | -218.7% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 29.0% | 36.1% | 54.3% | 56.0% |
| Operating Margin | 21.9% | -35.2% | 5.8% | 12.6% |
| Net Margin | -51.1% | -55.8% | -24.0% | -14.1% |
| FCF Margin | -25.3% | -8.5% | 15.5% | 15.5% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.05 | $0.01 | +120.0% | ||
| Q1'26 | $-0.07 | $-0.04 | +42.9% | ||
| Q4'25 | $-0.06 | $-0.08 | -33.3% | ||
| Q3'25 | $-0.06 | $-0.08 | -33.3% | ||
| Q2'25 | $-0.07 | $-0.08 | -14.3% | ||
| Q1'25 | $-0.03 | $-0.06 | -100.0% | ||
| Q4'24 | $-0.01 | $-0.02 | -150.0% | ||
| Q3'24 | $-0.04 | $-0.08 | -100.0% |
Total return is +158.7% (1Y), outperforming the benchmark by +133.7%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +52.9% | +43.6% | — |
| 1Y | +158.7% | +133.7% | — |
| 3YCAGR | -26.5% | -45.9% | — |
| 5YCAGR | -35.0% | -47.4% | — |
| 10YCAGR | -16.0% | -29.6% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Maravai LifeSciences Holdings, Inc. (MRVI) valuation, health, and returns.
Based on peer relative multiples, Maravai LifeSciences Holdings, Inc. appears Limited: Cheap versus peers compared to industry peers.
Maravai LifeSciences Holdings, Inc. has multiple valuation anchors: Peer Relative Fair Value: $16.44 | Wall Street Analyst Target: $6.00 (implying +15.4% upside). A convergence of these signals offers higher conviction.
Maravai LifeSciences Holdings, Inc. displays weak financial health with a composite quality score of 39/100, supported by a Altman Z-Score of 1.2 (distress zone), Piotroski F-Score of 2/9, Return on Invested Capital (ROIC) of -1.2%.
Maravai LifeSciences Holdings, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Maravai LifeSciences Holdings, Inc.'s current growth trajectory is Accelerating. The company achieved -28.3% 1Y revenue growth and +13.3% 1Y EPS growth, compared to its 3Y revenue CAGR of -40.5%.
Wall Street consensus is Buy based on 14 analysts, beating EPS expectations in 25% of recent quarters with a 2-quarter streak. The consensus price target represents a +15.4% change from current levels.
Investment risks for Maravai LifeSciences Holdings, Inc. include: -29.8% 1-year max drawdown, high beta (1.80x market volatility), elevated distress risk. Volatility risk is characterized by a beta of 1.80x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.